All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

When to refer patients with MPN to clinical trials: Part I - Patients with ET/PV

Mar 3, 2023
Learning objective: After reading this article, learners will be able to identify factors underlying the decision to refer patients with ET/PV to clinical trials.

The MPN Hub was pleased to speak to Laura Michaelis, Medical College of Wisconsin, Milwaukee, US and Anand Patel, University of Chicago, Chicago, US. We asked, When to refer patients with MPN to clinical trials: Part I — Patients with essential thrombocytopenia/polycythemia vera.

When to refer patients with MPN to clinical trials: Part I - Patients with ET/PV

In this podcast, Michaelis and Patel discuss the factors which determine whether standard of care treatment or referral to a clinical trial is the most appropriate course of action. Patel begins by outlining drugs currently under clinical trial for essential thrombocytopenia and polycythemia vera.  Michaelis and Patel then consider the importance of aligning trial endpoints with the individualized treatment goals of patients. They conclude by discussing how the progression of a patient to second-line therapy, as well as cytogenetic abnormalities that indicate more aggressive disease progression, may underly the decision to consider clinical trials that align with a patient’s goals.